The AKT inhibitor perifosine in biochemically recurrent prostate cancer: A phase II California/Pittsburgh cancer consortium trial

Karen G. Chee, Jeff Longmate, David I. Quinn, Gurkamal Chatta, Jacek Pinski, Przemyslaw Twardowski, Chong-Xian Pan, Angelo Cambio, Christopher P Evans, David R Gandara, Primo N Lara

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Background: Perifosine is an oral alkylphospholipid that inhibits cancer cell growth through decreased Akt phosphorylation. We conducted a phase II trial of perifosine in patients with biochemically recurrent, hormone-sensitive prostate cancer. Patients and Methods: Eligible patients had histologically confirmed prostate cancer, previous prostatectomy and/or radiation therapy, and rising prostate-specific antigen (PSA) without radiographic evidence of metastasis. Previous androgen deprivation therapy < 9 months in duration (completed ≥ 1 year before registration) was allowed. The primary endpoint was PSA response, defined as a decrease by ≥ 50% from the pretreatment value. Treatment was comprosed of a loading dose of perifosine 900 mg orally on day 1, then 100 mg daily starting 24 hours later. Results: Of 25 patients, 24 were evaluable for response. After a median follow-up of 8 months, 5 patients (20%) had a reduction in serum PSA levels, but none met criteria for PSA response. Three patients immediately progressed with no response to therapy. Median progression-free survival was 6.64 months (range, 4.53-12.81 months). No change in the PSA doubling time (7 months) was observed before and after treatment initiation. Dose-limiting toxicities (all grade 3) included hyponatremia, arthritis, hyperuricemia, and photophobia. Conclusion: Although well tolerated, perifosine did not meet prespecified PSA criteria for response as a single agent in biochemically recurrent prostate cancer. However, 20% of patients had evidence of PSA reduction, suggesting modest single-agent clinical activity. The role of perifosine in combination with androgen deprivation or chemotherapy is currently under investigation.

Original languageEnglish (US)
Pages (from-to)433-437
Number of pages5
JournalClinical Genitourinary Cancer
Volume5
Issue number7
DOIs
StatePublished - Dec 2007

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Neoplasms
Androgens
Photophobia
Hyperuricemia
Hyponatremia
Therapeutics
Prostatectomy
perifosine
Disease-Free Survival
Arthritis
Radiotherapy
Phosphorylation
Hormones
Neoplasm Metastasis
Drug Therapy
Growth
Serum

Keywords

  • Alkylphospholipids
  • Androgen deprivation therapy
  • Prostate-specific antigen

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

The AKT inhibitor perifosine in biochemically recurrent prostate cancer : A phase II California/Pittsburgh cancer consortium trial. / Chee, Karen G.; Longmate, Jeff; Quinn, David I.; Chatta, Gurkamal; Pinski, Jacek; Twardowski, Przemyslaw; Pan, Chong-Xian; Cambio, Angelo; Evans, Christopher P; Gandara, David R; Lara, Primo N.

In: Clinical Genitourinary Cancer, Vol. 5, No. 7, 12.2007, p. 433-437.

Research output: Contribution to journalArticle

Chee, Karen G. ; Longmate, Jeff ; Quinn, David I. ; Chatta, Gurkamal ; Pinski, Jacek ; Twardowski, Przemyslaw ; Pan, Chong-Xian ; Cambio, Angelo ; Evans, Christopher P ; Gandara, David R ; Lara, Primo N. / The AKT inhibitor perifosine in biochemically recurrent prostate cancer : A phase II California/Pittsburgh cancer consortium trial. In: Clinical Genitourinary Cancer. 2007 ; Vol. 5, No. 7. pp. 433-437.
@article{fb3f9fcda6b04c07b8af5cbb3dd577c2,
title = "The AKT inhibitor perifosine in biochemically recurrent prostate cancer: A phase II California/Pittsburgh cancer consortium trial",
abstract = "Background: Perifosine is an oral alkylphospholipid that inhibits cancer cell growth through decreased Akt phosphorylation. We conducted a phase II trial of perifosine in patients with biochemically recurrent, hormone-sensitive prostate cancer. Patients and Methods: Eligible patients had histologically confirmed prostate cancer, previous prostatectomy and/or radiation therapy, and rising prostate-specific antigen (PSA) without radiographic evidence of metastasis. Previous androgen deprivation therapy < 9 months in duration (completed ≥ 1 year before registration) was allowed. The primary endpoint was PSA response, defined as a decrease by ≥ 50{\%} from the pretreatment value. Treatment was comprosed of a loading dose of perifosine 900 mg orally on day 1, then 100 mg daily starting 24 hours later. Results: Of 25 patients, 24 were evaluable for response. After a median follow-up of 8 months, 5 patients (20{\%}) had a reduction in serum PSA levels, but none met criteria for PSA response. Three patients immediately progressed with no response to therapy. Median progression-free survival was 6.64 months (range, 4.53-12.81 months). No change in the PSA doubling time (7 months) was observed before and after treatment initiation. Dose-limiting toxicities (all grade 3) included hyponatremia, arthritis, hyperuricemia, and photophobia. Conclusion: Although well tolerated, perifosine did not meet prespecified PSA criteria for response as a single agent in biochemically recurrent prostate cancer. However, 20{\%} of patients had evidence of PSA reduction, suggesting modest single-agent clinical activity. The role of perifosine in combination with androgen deprivation or chemotherapy is currently under investigation.",
keywords = "Alkylphospholipids, Androgen deprivation therapy, Prostate-specific antigen",
author = "Chee, {Karen G.} and Jeff Longmate and Quinn, {David I.} and Gurkamal Chatta and Jacek Pinski and Przemyslaw Twardowski and Chong-Xian Pan and Angelo Cambio and Evans, {Christopher P} and Gandara, {David R} and Lara, {Primo N}",
year = "2007",
month = "12",
doi = "10.3816/CGC.2007.n.031",
language = "English (US)",
volume = "5",
pages = "433--437",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "7",

}

TY - JOUR

T1 - The AKT inhibitor perifosine in biochemically recurrent prostate cancer

T2 - A phase II California/Pittsburgh cancer consortium trial

AU - Chee, Karen G.

AU - Longmate, Jeff

AU - Quinn, David I.

AU - Chatta, Gurkamal

AU - Pinski, Jacek

AU - Twardowski, Przemyslaw

AU - Pan, Chong-Xian

AU - Cambio, Angelo

AU - Evans, Christopher P

AU - Gandara, David R

AU - Lara, Primo N

PY - 2007/12

Y1 - 2007/12

N2 - Background: Perifosine is an oral alkylphospholipid that inhibits cancer cell growth through decreased Akt phosphorylation. We conducted a phase II trial of perifosine in patients with biochemically recurrent, hormone-sensitive prostate cancer. Patients and Methods: Eligible patients had histologically confirmed prostate cancer, previous prostatectomy and/or radiation therapy, and rising prostate-specific antigen (PSA) without radiographic evidence of metastasis. Previous androgen deprivation therapy < 9 months in duration (completed ≥ 1 year before registration) was allowed. The primary endpoint was PSA response, defined as a decrease by ≥ 50% from the pretreatment value. Treatment was comprosed of a loading dose of perifosine 900 mg orally on day 1, then 100 mg daily starting 24 hours later. Results: Of 25 patients, 24 were evaluable for response. After a median follow-up of 8 months, 5 patients (20%) had a reduction in serum PSA levels, but none met criteria for PSA response. Three patients immediately progressed with no response to therapy. Median progression-free survival was 6.64 months (range, 4.53-12.81 months). No change in the PSA doubling time (7 months) was observed before and after treatment initiation. Dose-limiting toxicities (all grade 3) included hyponatremia, arthritis, hyperuricemia, and photophobia. Conclusion: Although well tolerated, perifosine did not meet prespecified PSA criteria for response as a single agent in biochemically recurrent prostate cancer. However, 20% of patients had evidence of PSA reduction, suggesting modest single-agent clinical activity. The role of perifosine in combination with androgen deprivation or chemotherapy is currently under investigation.

AB - Background: Perifosine is an oral alkylphospholipid that inhibits cancer cell growth through decreased Akt phosphorylation. We conducted a phase II trial of perifosine in patients with biochemically recurrent, hormone-sensitive prostate cancer. Patients and Methods: Eligible patients had histologically confirmed prostate cancer, previous prostatectomy and/or radiation therapy, and rising prostate-specific antigen (PSA) without radiographic evidence of metastasis. Previous androgen deprivation therapy < 9 months in duration (completed ≥ 1 year before registration) was allowed. The primary endpoint was PSA response, defined as a decrease by ≥ 50% from the pretreatment value. Treatment was comprosed of a loading dose of perifosine 900 mg orally on day 1, then 100 mg daily starting 24 hours later. Results: Of 25 patients, 24 were evaluable for response. After a median follow-up of 8 months, 5 patients (20%) had a reduction in serum PSA levels, but none met criteria for PSA response. Three patients immediately progressed with no response to therapy. Median progression-free survival was 6.64 months (range, 4.53-12.81 months). No change in the PSA doubling time (7 months) was observed before and after treatment initiation. Dose-limiting toxicities (all grade 3) included hyponatremia, arthritis, hyperuricemia, and photophobia. Conclusion: Although well tolerated, perifosine did not meet prespecified PSA criteria for response as a single agent in biochemically recurrent prostate cancer. However, 20% of patients had evidence of PSA reduction, suggesting modest single-agent clinical activity. The role of perifosine in combination with androgen deprivation or chemotherapy is currently under investigation.

KW - Alkylphospholipids

KW - Androgen deprivation therapy

KW - Prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=38949099997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949099997&partnerID=8YFLogxK

U2 - 10.3816/CGC.2007.n.031

DO - 10.3816/CGC.2007.n.031

M3 - Article

C2 - 18272025

AN - SCOPUS:38949099997

VL - 5

SP - 433

EP - 437

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 7

ER -